Related Experiment Video
Updated: Jun 5, 2026
05:30
Controlled Cortical Impact Model for Traumatic Brain Injury
Published on: August 5, 2014
Progesterone for acute traumatic brain injury.
Ma Junpeng1, Siqing Huang, Shu Qin
1Department of Neurological Surgery, West China Hospital, Sichuan University, No. 37, Guo Xue Xiang, Chengdu, Sichuan, China, 610041.
The Cochrane Database of Systematic Reviews
|January 21, 2011
Summary
Progesterone may reduce mortality and severe disability in traumatic brain injury (TBI) patients. However, more multicenter randomized controlled trials are needed to confirm these findings.
Area of Science:
- Neuroscience
- Trauma Care
- Pharmacology
Background:
- Traumatic brain injury (TBI) is a significant cause of mortality and long-term disability.
- Progesterone is being investigated as a potential neuroprotective agent for TBI treatment.
Purpose of the Study:
- To evaluate the efficacy and safety of progesterone in individuals with acute traumatic brain injury (TBI).
Main Methods:
- A systematic review of published and unpublished randomized controlled trials (RCTs) was conducted.
- Searches included major databases like Cochrane, MEDLINE, EMBASE, and LILACS up to April 2010.
- Three RCTs involving 315 patients met the inclusion criteria for analysis.
Main Results:
- Progesterone administration was associated with a reduced risk of mortality (RR 0.61, 95% CI 0.40 to 0.93).
- A decreased risk of death or severe disability was observed in patients treated with progesterone (RR 0.77, 95% CI 0.62 to 0.96).
- Limited data were available on intracranial pressure and adverse events; no significant heterogeneity was detected.
Conclusions:
- Preliminary evidence from small RCTs suggests progesterone may improve neurological outcomes in TBI patients.
- The current evidence is insufficient, underscoring the need for larger, multicenter RCTs to confirm these effects.
